110 related articles for article (PubMed ID: 34243618)
1. Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for treatment of non-small cell lung cancer.
Chraibi S; Rosière R; De Prez E; Gérard P; Antoine MH; Langer I; Nortier J; Remmelink M; Amighi K; Wauthoz N
Biomed Pharmacother; 2021 Jul; 139():111716. PubMed ID: 34243618
[TBL] [Abstract][Full Text] [Related]
2. The combination of an innovative dry powder for inhalation and a standard cisplatin-based chemotherapy in view of therapeutic intensification against lung tumours.
Chraibi S; Rosière R; Larbanoix L; Gérard P; Hennia I; Laurent S; Vermeersch M; Amighi K; Wauthoz N
Eur J Pharm Biopharm; 2021 Jul; 164():93-104. PubMed ID: 33957225
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
[TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
Nakao A; Uchino J; Igata F; On R; Ikeda T; Yatsugi H; Hirano R; Sasaki T; Tanimura K; Imabayashi T; Tamiya N; Kaneko Y; Yamada T; Nagata N; Watanabe K; Kishimoto J; Takayama K; Fujita M
Invest New Drugs; 2018 Oct; 36(5):903-910. PubMed ID: 29846848
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary and renal tolerance of cisplatin-based regimens combining intravenous and endotracheal routes for lung cancer treatment in mice.
Chraibi S; Rosière R; De Prez E; Antoine MH; Remmelink M; Langer I; Nortier J; Amighi K; Wauthoz N
Int J Pharm; 2021 Apr; 599():120425. PubMed ID: 33647417
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.
Rosell R; Gatzemeier U; Betticher DC; Keppler U; Macha HN; Pirker R; Berthet P; Breau JL; Lianes P; Nicholson M; Ardizzoni A; Chemaissani A; Bogaerts J; Gallant G
Ann Oncol; 2002 Oct; 13(10):1539-49. PubMed ID: 12377641
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
[TBL] [Abstract][Full Text] [Related]
8. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
Johnson DH; Paul DM; Hande KR; DeVore R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA
Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.
Engel-Riedel W; Lowe J; Mattson P; Richard Trout J; Huhn RD; Gargano M; Patchen ML; Walsh R; Trinh MM; Dupuis M; Schneller F
J Immunother Cancer; 2018 Feb; 6(1):16. PubMed ID: 29486797
[TBL] [Abstract][Full Text] [Related]
12. Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer (NSCLC).
Kaplan B; Altýnbas M; Eroglu C; Karahacioglu E; Er O; Ozkan M; Bilgin M; Canoz O; Gulmez I; Gulec M
Am J Clin Oncol; 2004 Dec; 27(6):603-10. PubMed ID: 15577439
[TBL] [Abstract][Full Text] [Related]
13. Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer.
De Giorgi U; Rosti G; Ciucci G; Kopf B; Minzi C; Argnani M; Marangolo M
Bone Marrow Transplant; 2007 Oct; 40(8):735-9. PubMed ID: 17700603
[TBL] [Abstract][Full Text] [Related]
14. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
Fang Y; Wang L; Xia GH; Shi MQ
Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858
[TBL] [Abstract][Full Text] [Related]
15. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
[TBL] [Abstract][Full Text] [Related]
16. A Phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly.
Chen YM; Perng RP; Tsai CM; Whang-Peng J
J Thorac Oncol; 2006 Feb; 1(2):141-5. PubMed ID: 17409843
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel (Taxol) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC.
Isokangas OP; Joensuu H; Halme M; Jekunen A; Mattson K
Lung Cancer; 1998 May; 20(2):127-33. PubMed ID: 9711531
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness of weekly paclitaxel for patients with advanced non-small cell lung cancer].
Suyama H; Hitsuda Y; Matsumoto S; Nakamoto M; Shigeoka Y; Nakanishi H; Igishi T; Burioka N; Yasuda K; Sako T; Miyata M; Endo M; Shimizu E
Gan To Kagaku Ryoho; 2003 Mar; 30(3):365-70. PubMed ID: 12669395
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy with carboplatin-paclitaxel followed by standard radiotherapy with concurrent daily low-dose cisplatin plus weekly paclitaxel for inoperable non-small-cell lung cancer.
Ardizzoni A; Scolaro T; Mereu C; Cafferata MA; Tixi L; Bacigalupo A; Tiseo M; Monetti F; Rosso R
Am J Clin Oncol; 2005 Feb; 28(1):58-64. PubMed ID: 15685036
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF
J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
